{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:40:36Z","timestamp":1787244036988,"version":"build-2736575974"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n The Primary Care Opioid Use Disorders (PROUD) treatment trial was a 2-year implementation trial that demonstrated the Massachusetts office-based addiction treatment (OBAT) model of nurse care management for opioid use disorder (OUD) increased OUD treatment in the 2 years after implementation began (8.2 more patient-years of OUD treatment per 10\u202f000 primary care patients). The intervention was continued for a third year, permitting evaluation of 3-year outcomes.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare OUD medication treatment in intervention and usual care clinics over 3 years of implementation.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This is a preplanned secondary analysis of a cluster randomized implementation trial, conducted in 6 health systems in 5 states (2 primary care clinics per health system) with clinic randomization stratified by system (assignment notification February 28, 2018 [August 31, 2018, in 1 system]). Data were obtained from electronic health records and insurance claims. Eligible patients were those aged 16 to 90 years visiting intervention or usual care clinics from 3 years before to 2 years after randomization. Patients new to clinics during the third year after randomization could not be included because COVID-19\u2013era transitions to virtual care precluded assignment of patients to clinics. Data analysis occurred from November 2023 to September 2024.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Clinics were randomized to intervention or care as usual. Intervention included 3 implementation components: salary for 1 full-time OBAT nurse per intervention clinic; training and ongoing technical assistance for nurses; and 3 or more primary care buprenorphine prescribers.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n Patient-years of OUD treatment (buprenorphine or extended-release naltrexone) per 10\u202f000 primary care patients in the 3 years postrandomization. Mixed-effect models adjusted for baseline values of the outcome and included a health system\u2013specific random intercept to account for correlation of clinic pairs within a system.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Prerandomization, a total of 290\u202f071 primary care patients were seen, including 130\u202f618 in intervention clinics (mean [SD] age, 48.6 [17.7] years; mean [SD] female, 59.3% [4.0%]) and 159\u202f453 in usual care clinics (mean [SD] age, 47.2 [17.5] years; mean [SD] female, 64.0% [5.3%]). Over 3 years postrandomization, intervention clinics provided 19.7 (95% CI, 11.1-28.4) more patient-years of OUD treatment per 10\u202f000 primary care patients compared with usual care clinics.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In this secondary analysis of the PROUD cluster randomized trial, after an added year of the intervention, OUD treatment continued to increase in intervention clinics compared with usual care. The treatment increase over 3 years exceeded that of the first 2 years, suggesting that implementation of the Massachusetts OBAT model leads to ongoing increases in OUD treatment among primary care patients in the third year of implementation.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03407638<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.47447","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T11:31:29Z","timestamp":1732275089000},"page":"e2447447","source":"Crossref","is-referenced-by-count":10,"title":["Nurse Care Management of Opioid Use Disorder Treatment After 3 Years"],"prefix":"10.1001","volume":"7","author":[{"given":"Gwen T.","family":"Lapham","sequence":"first","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle, Washington"},{"name":"Department of Health Systems and Population Health, School of Public Health, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noorie","family":"Hyun","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer F.","family":"Bobb","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige D.","family":"Wartko","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle, Washington"},{"name":"Department of Epidemiology, School of Public Health, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail G.","family":"Matthews","sequence":"additional","affiliation":[{"name":"The Emmes Company, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onchee","family":"Yu","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McCormack","sequence":"additional","affiliation":[{"name":"The Emmes Company, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Lee","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Liu","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse Center for Clinical Trials Network, North Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Samet","sequence":"additional","affiliation":[{"name":"Boston University Chobanian and Avedisian School of Medicine and the School of Public Health, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Zare-Mehrjerdi","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, UTHealth Houston McGovern Medical School, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Braciszewski","sequence":"additional","affiliation":[{"name":"Center for Health Policy and Health Services Research, Henry Ford Health, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Murphy","sequence":"additional","affiliation":[{"name":"MultiCare Health System, Tacoma, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia H.","family":"Arnsten","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center, Bronx, New York"},{"name":"Albert Einstein College of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Horigian","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Caldeiro","sequence":"additional","affiliation":[{"name":"Mental Health and Wellness Department, Kaiser Permanente Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Addis","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine A.","family":"Bradley","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle, Washington"},{"name":"Department of Health Systems and Population Health, School of Public Health, University of Washington, Seattle"},{"name":"Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"issue":"6","key":"zoi241341r1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013-2019.","volume":"70","author":"Mattson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"21","key":"zoi241341r4","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1001\/jama.2019.5523","article-title":"Medication-based treatment to address opioid use disorder.","volume":"321","author":"Leshner","year":"2019","journal-title":"JAMA"},{"key":"zoi241341r5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.drugalcdep.2016.10.015","article-title":"Treatment utilization among persons with opioid use disorder in the United States.","volume":"169","author":"Wu","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"zoi241341r6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jsat.2020.02.001","article-title":"Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems.","volume":"112S","author":"Boudreau","year":"2020","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"zoi241341r7","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/ADM.0000000000000164","article-title":"Patterns and quality of buprenorphine opioid agonist treatment in a large Medicaid program.","volume":"9","author":"Gordon","year":"2015","journal-title":"J Addict Med"},{"issue":"4","key":"zoi241341r8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2149","article-title":"Primary care-based models for the treatment of opioid use disorder: a scoping review.","volume":"166","author":"Korthuis","year":"2017","journal-title":"Ann Intern Med"},{"issue":"10","key":"zoi241341r9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186315","article-title":"Primary care models for treating opioid use disorders: what actually works? A systematic review.","volume":"12","author":"Lagisetty","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"zoi241341r10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11920-020-01149-0","article-title":"Identification and management of opioid use disorder in primary care: an update.","volume":"22","author":"Donroe","year":"2020","journal-title":"Curr Psychiatry Rep"},{"key":"zoi241341r11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jsat.2015.06.010","article-title":"Office-based opioid treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts collaborative care model in community health centers.","volume":"60","author":"LaBelle","year":"2016","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"zoi241341r15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","article-title":"Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.","volume":"171","author":"Alford","year":"2011","journal-title":"Arch Intern Med"},{"issue":"12","key":"zoi241341r16","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1001\/jamainternmed.2023.5701","article-title":"Nurse care management for opioid use disorder treatment: the PROUD cluster randomized clinical trial.","volume":"183","author":"Wartko","year":"2023","journal-title":"JAMA Intern Med"},{"key":"zoi241341r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108633","article-title":"\u201cI didn\u2019t feel like a number\u201d: the impact of nurse care managers on the provision of buprenorphine treatment in primary care settings.","volume":"132","author":"Beharie","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"zoi241341r18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e5661","article-title":"Consort 2010 statement: extension to cluster randomised trials.","volume":"345","author":"Campbell","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"zoi241341r19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13722-021-00218-w","article-title":"Primary care opioid use disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment.","volume":"16","author":"Campbell","year":"2021","journal-title":"Addict Sci Clin Pract"},{"issue":"4","key":"zoi241341r20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1553-7250(08)34030-6","article-title":"A practical, robust implementation and sustainability model (PRISM) for integrating research findings into practice.","volume":"34","author":"Feldstein","year":"2008","journal-title":"Jt Comm J Qual Patient Saf"},{"issue":"9","key":"zoi241341r21","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2105\/AJPH.89.9.1322","article-title":"Evaluating the public health impact of health promotion interventions: the RE-AIM framework.","volume":"89","author":"Glasgow","year":"1999","journal-title":"Am J Public Health"},{"issue":"6","key":"zoi241341r22","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.2105\/AJPH.2013.301299","article-title":"The RE-AIM framework: a systematic review of use over time.","volume":"103","author":"Gaglio","year":"2013","journal-title":"Am J Public Health"},{"issue":"3","key":"zoi241341r27","doi-asserted-by":"publisher","first-page":"e223821","DOI":"10.1001\/jamanetworkopen.2022.3821","article-title":"Use of medication for opioid use disorder among Us adolescents and adults with need for opioid treatment, 2019.","volume":"5","author":"Mauro","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi241341r29","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/biostatistics\/kxaa007","article-title":"Randomization-based confidence intervals for cluster randomized trials.","volume":"22","author":"Rabideau","year":"2021","journal-title":"Biostatistics"},{"issue":"1","key":"zoi241341r31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13722-021-00259-1","article-title":"Fluctuations in barriers to medication treatment for opioid use disorder prescribing over the course of a one-year external facilitation intervention.","volume":"16","author":"Gustavson","year":"2021","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"zoi241341r32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s43058-021-00119-8","article-title":"Early impacts of a multi-faceted implementation strategy to increase use of medication treatments for opioid use disorder in the Veterans Health Administration.","volume":"2","author":"Gustavson","year":"2021","journal-title":"Implement Sci Commun"},{"issue":"4","key":"zoi241341r33","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1097\/ADM.0000000000001156","article-title":"Clinician perspectives on delivering medication treatment for opioid use disorder during the COVID-19 pandemic: a qualitative evaluation.","volume":"17","author":"Lott","year":"2023","journal-title":"J Addict Med"},{"issue":"9","key":"zoi241341r34","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/jama.2023.1090","article-title":"A 2023 agenda for substance use prevention and treatment in the US.","volume":"329","author":"Gupta","year":"2023","journal-title":"JAMA"},{"key":"zoi241341r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.110981","article-title":"Trends in buprenorphine dosage and days supplied for new treatment episodes for opioid use disorder, 2010-2019.","volume":"252","author":"Tilhou","year":"2023","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"zoi241341r36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.","author":"Mattick","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"zoi241341r37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.52381","article-title":"Telemedicine use and quality of opioid use disorder treatment in the US during the COVID-19 pandemic.","volume":"6","author":"Hailu","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi241341r38","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/jrh.12570","article-title":"An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.","volume":"37","author":"Hughes","year":"2021","journal-title":"J Rural Health"},{"key":"zoi241341r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108222","article-title":"Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19.","volume":"122","author":"Livingston","year":"2021","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"zoi241341r40","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1080\/00952990.2021.1903023","article-title":"Common themes in early state policy responses to substance use disorder treatment during COVID-19.","volume":"47","author":"Andraka-Christou","year":"2021","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"11","key":"zoi241341r41","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.3833","article-title":"Assessment of state and federal health policies for opioid use disorder treatment during the COVID-19 pandemic and beyond.","volume":"2","author":"Pessar","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"1","key":"zoi241341r42","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13063-020-4148-z","article-title":"Addressing identification bias in the design and analysis of cluster-randomized pragmatic trials: a case study.","volume":"21","author":"Bobb","year":"2020","journal-title":"Trials"},{"key":"zoi241341r28","doi-asserted-by":"crossref","DOI":"10.1201\/9780429246593","volume-title":"An introduction to the bootstrap","author":"Efron","year":"1994"},{"key":"zoi241341r2","unstructured":"National Center for Health Statistics. Drug overdose deaths in the US top 100,000 annually. Centers for Disease Control and Prevention. Updated November 17, 2021. Accessed October 17, 2024. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2021\/20211117.htm"},{"key":"zoi241341r3","doi-asserted-by":"crossref","unstructured":"Mancher? M, Leshner? AI, eds. Medications for Opioid Use Disorder Saves Lives. National Academies of Sciences, Engineering, and Medicine. Published March 30, 2019. Accessed October 17, 2024. https:\/\/nap.nationalacademies.org\/catalog\/25310\/medications-for-opioid-use-disorder-save-lives","DOI":"10.17226\/25310"},{"key":"zoi241341r12","unstructured":"World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Published 2009. Accessed June 11, 2018. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK143185\/"},{"key":"zoi241341r13","unstructured":"Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder for healthcare and addiction professionals, policymakers, patients, and families: treatment improvement protocol. 63. 2021. Accessed October 17, 2024. https:\/\/store.samhsa.gov\/sites\/default\/files\/pep21-02-01-002.pdf"},{"key":"zoi241341r14","unstructured":"American Society of Addiction Medicine. Public policy statement on the regulation of office-based opioid treatment. January 17, 2018. Accessed October 17, 2024. https:\/\/www.asam.org\/docs\/default-source\/public-policy-statements\/statement-on-regulation-of-obot.pdf"},{"key":"zoi241341r23","unstructured":"Boston Medical Center. Office based addiction treatment training and technical assistance\u2014Massachusetts nurse care manager model of office-based addiction treatment: clinical guidelines. Updated April 2021. Accessed October 17, 2024. https:\/\/www.addictiontraining.org\/documents\/resources\/22_2021_Clinical_Guidelines_1.12.2022_fp_th%2528003%2529.29.pdf"},{"key":"zoi241341r24","unstructured":"National Quality Forum. Opioids and opioid use disorder: quality measurement priorities. Published February 2020. Accessed October 17, 2024. https:\/\/www.qualityforum.org\/Publications\/2020\/02\/Opioids_and_Opioid_Use_Disorder__Quality_Measurement_Priorities.aspx"},{"key":"zoi241341r25","unstructured":"Mark? TL, McGaffey? F, Koppelman? J, Yastishock? V. State Measures for improving opioid use disorder treatment implementation toolkit. RTI International. Published 2022. Accessed October 17, 2024. https:\/\/www.pewtrusts.org\/-\/media\/assets\/2022\/11\/14798_pew_metrics_toolkit_111722.pdf"},{"key":"zoi241341r26","unstructured":"National Quality Forum. Continuity of pharmacotherapy for opioid use disorder (OUD). Centers for Medicare & Medicaid Services. 2019. Accessed October 17, 2024. https:\/\/qpp.cms.gov\/docs\/QPP_quality_measure_specifications\/CQM-Measures\/2019_Measure_468_MIPSCQM.pdf"},{"key":"zoi241341r30","unstructured":"R Core Team . The R project for statistical computing. Accessed October 17, 2024. https:\/\/www.R-project.org\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2826722\/lapham_2024_oi_241341_1731684047.56958.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T11:31:35Z","timestamp":1732275095000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2826722"}},"subtitle":["A Secondary Analysis of the PROUD Cluster Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.47447","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]}}}